Drugs / Daunorubicin 60 mg/m2 IV (in the vein) daily 1,2,3 Courses 1A, 2A
Daunorubicin 60 mg/m2 IV (in the vein) daily 1,2,3 Courses 1A, 2A
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02043587 | Jan 2014 → Apr 2022 | acute lymphoblastic leukemia | University of California, San Diego | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Daunorubicin 60 mg/m2 IV (in the vein) daily 1,2,3 Courses 1A, 2A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02043587 ↗ |
| Route | Intravenous | “Daunorubicin 60 mg/m2 IV (in the vein) daily 1,2,3 Courses 1A, 2A” NCT02043587 ↗ |